418 related articles for article (PubMed ID: 25986624)
1. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
[TBL] [Abstract][Full Text] [Related]
2. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
3. Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma.
Saji H; Sakai H; Kimura H; Miyazawa T; Marushima H; Nakamura H
Onco Targets Ther; 2017; 10():4135-4141. PubMed ID: 28860823
[TBL] [Abstract][Full Text] [Related]
4. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
5. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
6. Plasma EGFR Mutation Detection Associated With Survival Outcomes in Advanced-Stage Lung Cancer.
Lam DC; Tam TC; Lau KM; Wong WM; Hui CK; Lam JC; Wang JK; Lui MM; Ho JC; Ip MS
Clin Lung Cancer; 2015 Nov; 16(6):507-13. PubMed ID: 26239567
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
[TBL] [Abstract][Full Text] [Related]
8. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma.
Zhang Y; Li J; Wang R; Li Y; Pan Y; Cai D; Hu H; Li H; Ye T; Luo X; Zhang Y; Li B; Shen L; Sun Y; Chen H
Sci Rep; 2014 Nov; 4():7163. PubMed ID: 25418354
[TBL] [Abstract][Full Text] [Related]
9. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
Isaka T; Nakayama H; Ito H; Yokose T; Yamada K; Masuda M
BMC Cancer; 2018 Oct; 18(1):959. PubMed ID: 30290774
[TBL] [Abstract][Full Text] [Related]
10. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
11. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
13. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
[TBL] [Abstract][Full Text] [Related]
14. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery.
Ahn HK; Choi YL; Han JH; Ahn YC; Kim K; Kim J; Shim YM; Um SW; Kim H; Kwon OJ; Sun JM; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2013 Mar; 79(3):300-6. PubMed ID: 23261144
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
Lin CY; Wu YM; Hsieh MH; Wang CW; Wu CY; Chen YJ; Fang YF
PLoS One; 2017; 12(10):e0186567. PubMed ID: 29065153
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
